Hansa Biopharma AB (publ)

OM:HNSA Stock Report

Market Cap: SEK 2.3b

Hansa Biopharma (HNSA) Stock Overview

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. More details

HNSA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

HNSA Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

SEK 56.39
FV
51.9% undervalued intrinsic discount
92.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
about 21 hours ago author updated this narrative

Hansa Biopharma AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hansa Biopharma
Historical stock prices
Current Share PriceSEK 27.14
52 Week HighSEK 57.30
52 Week LowSEK 19.58
Beta1.54
1 Month Change3.59%
3 Month Change24.04%
1 Year Change-46.94%
3 Year Change-49.08%
5 Year Change-89.23%
Change since IPO146.73%

Recent News & Updates

Recent updates

author-image

Idefirix Expansion And Clinical Trials Will Open New Markets

Expanding Idefirix in Europe and securing reimbursements may enhance revenue by increasing market penetration and adoption rates.

Downgrade: Here's How Analysts See Hansa Biopharma AB (publ) (STO:HNSA) Performing In The Near Term

Feb 12
Downgrade: Here's How Analysts See Hansa Biopharma AB (publ) (STO:HNSA) Performing In The Near Term

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Feb 09
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

It's Down 26% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Feb 08
It's Down 26% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Dec 22
Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Nov 07
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Oct 20
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Aug 24
Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21
Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

May 21
Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05
Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28
Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13
Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Sep 22
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

May 31
Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Shareholder Returns

HNSASE BiotechsSE Market
7D3.4%-0.07%0.9%
1Y-46.9%-8.5%-1.0%

Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned -8.5% over the past year.

Return vs Market: HNSA underperformed the Swedish Market which returned -1% over the past year.

Price Volatility

Is HNSA's price volatile compared to industry and market?
HNSA volatility
HNSA Average Weekly Movement9.6%
Biotechs Industry Average Movement10.4%
Market Average Movement6.4%
10% most volatile stocks in SE Market13.8%
10% least volatile stocks in SE Market3.5%

Stable Share Price: HNSA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: HNSA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
2007138Renee Aguiar-Lucanderwww.hansabiopharma.com

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.

Hansa Biopharma AB (publ) Fundamentals Summary

How do Hansa Biopharma's earnings and revenue compare to its market cap?
HNSA fundamental statistics
Market capSEK 2.30b
Earnings (TTM)-SEK 625.74m
Revenue (TTM)SEK 181.68m
12.7x
P/S Ratio
-3.7x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HNSA income statement (TTM)
RevenueSEK 181.68m
Cost of RevenueSEK 85.93m
Gross ProfitSEK 95.76m
Other ExpensesSEK 721.50m
Earnings-SEK 625.74m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 17, 2025

Earnings per share (EPS)-7.38
Gross Margin52.71%
Net Profit Margin-344.41%
Debt/Equity Ratio-161.1%

How did HNSA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/10 18:38
End of Day Share Price 2025/07/10 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hansa Biopharma AB (publ) is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Christian LeeABG Sundal Collier Sponsored
Madhu KumarB. Riley Securities, Inc.